Applied Molecular Transport

Applied Molecular Transport, Inc. is a clinical-stage biopharmaceutical company, which engages in the design and development of a pipeline of novel oral biologic product candidates for the treatment of autoimmune, inflammatory, and metabolic diseases. The company was founded by Tahir Mahmood and Randall J. Mrsny on November 21, 2016 and is headquartered in South San Francisco, CA.

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Applied Molecular Transport, Inc. is a clinical-stage biopharmaceutical company, which engages in the design and development of a pipeline of novel oral biologic product candidates for the treatment of autoimmune, inflammatory, and metabolic diseases. The company was founded by Tahir Mahmood on November 21, 2016 and is headquartered in Menlo Park, CA.

Cyclo Therapeutics, Inc.

GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company focused on developing transformative therapies for rare and neurological diseases with limited treatment options, and Applied Molecular Transport Inc. (Nasdaq: AMTI) (“AMT”), a biopharmaceutical company, announced today the closing of its previously announced transaction pursuant to which AMT will merge with Cyclo Therapeutics in an all-stoc.

Cyclo Therapeutics, Inc. Completes Merger with Applied Molecular Transport Inc.

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Applied Molecular Transport Inc. (NasdaqCM: AMTI) to Cyclo Therapeutics, Inc. (NasdaqCM: CYTH). Under the terms of the proposed transaction, shareholders of Applied Molecular will receive 0.174 shares of Cyclo for each share of Applied Molecular that they own. KSF is seeking to determine whether this considera.

APPLIED MOLECULAR INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Applied Molecular Transport Inc. - AMTI

Company Entered into Definitive Merger Agreement with Cyclo Therapeutics Cash and Cash Equivalents of $18.1 million, as of September 30, 2023 SOUTH SAN FRANCISCO, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a biopharmaceutical company, today reported financial results for the third quarter ended September 30, 2023.

Applied Molecular Transport Reports Third Quarter 2023 Financial Results

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Applied Molecular Transport Inc. (NASDAQ: AMTI) to Cyclo Therapeutics, Inc. for 0.174 shares of Cyclo for each share of Applied Molecular is fair to Applied Molecular shareholders. Halper Sadeh encourages Applied Molecular shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or.

AMTI Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Applied Molecular Transport Inc. Is Fair to Shareholders

GAINESVILLE, Fla. & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company focused on developing transformative therapies for rare and neurological diseases with limited treatment options, and Applied Molecular Transport Inc. (Nasdaq: AMTI) (“AMT”), a biopharmaceutical company, announced today that the companies have entered into a definitive agreement (the Merger Agreement) pursuant t.

Cyclo Therapeutics, Inc. and Applied Molecular Transport Inc. Enter into a Definitive Merger Agreement

Currently Pursuing Strategic Alternatives, with MTS Health Partners, L.P. Advising the Company Cash and Cash Equivalents of $22.5 million, as of June 30, 2023 SOUTH SAN FRANCISCO, Calif.

Applied Molecular Transport Reports Second Quarter 2023 Financial Results

SOUTH SAN FRANCISCO, Calif., March 27, 2023 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that the company's board of directors approved a workforce reduction of approximately 57% of its employee base and the engagement of MTS Health Partners, L.P. as advisors in a process to explore strategic alternatives for the company. As part of the restructuring, Tahir Mahmood, Ph.D., will leave his post as chief executive officer, but will remain as a board member. Shawn Cross, president and chief operating officer, will now serve as chief executive officer and has been appointed to the board where he will serve as chair.

Applied Molecular Transport Announces Corporate Leadership Change and Process to Explore Strategic Alternatives

Applied Molecular Transport Inc. (AMTI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

What Makes Applied Molecular Transport Inc. (AMTI) a New Buy Stock

Exploring strategic partnership options to advance AMT-101 for chronic pouchitis, an orphan indication with no  FDA-approved products

Applied Molecular Transport Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

New positive data demonstrate oral AMT-101's gut-restricted profile with tissue-level pharmacodynamics (PD) effects and no systemic exposure by design

Applied Molecular Transport Presents Additional Data from Oral AMT-101 Phase 2 FILLMORE Trial in Chronic Pouchitis at ECCO '23 Congress

Here is how Applied Molecular Transport Inc. (AMTI) and Edwards Lifesciences (EW) have performed compared to their sector so far this year.

Is Applied Molecular Transport (AMTI) Stock Outpacing Its Medical Peers This Year?

– Similar clinical remission rates observed in patients receiving AMT-101 monotherapy compared to placebo at week 12

Applied Molecular Transport Announces Top-line Phase 2 Results from LOMBARD Monotherapy Trial of Oral AMT-101 in Patients with Moderate-to-Severe Ulcerative Colitis

SOUTH SAN FRANCISCO, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT) today announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation for AMT-101 in patients with pouchitis, an indication with significant unmet medical need and no current FDA-approved products. AMT-101 is an investigational, once-daily, GI-selective, oral fusion of IL-10 and AMT's proprietary carrier molecule, which is also in development for the treatment of ulcerative colitis (UC) and rheumatoid arthritis (RA).

Applied Molecular Transport Announces FDA Orphan Drug Designation Granted to AMT-101 for Treatment of Pouchitis

SOUTH SAN FRANCISCO, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced its participation at the following investor conferences:

Applied Molecular Transport to Present at Upcoming November Investor Conferences

Company held end of Phase 2 meeting with FDA to discuss advancing oral AMT-101 monotherapy to Phase 3 in chronic pouchitis, an orphan indication with no FDA-approved products

Applied Molecular Transport Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Announced positive top-line data for AMT-101 FILLMORE Phase 2 trial in chronic pouchitis

Applied Molecular Transport Reports Second Quarter 2022 Financial Results and Provides Corporate Update

New York, New York--(Newsfile Corp. - July 28, 2022) - Pomerantz LLP is investigating claims on behalf of investors of Applied Molecular Transport Inc. ("Applied Molecular" or the "Company") (NASDAQ: AMTI). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Applied Molecular and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Applied Molecular Transport Inc. - AMTI

Los Angeles, California--(Newsfile Corp. - July 12, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Applied Molecular Transport Inc. ("Applied Molecular" or "the Company") (NASDAQ: AMTI) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Applied Molecular issued a press release on July 6,...

ONGOING INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Applied Molecular Transport Inc. with Losses of $100,000 to Contact the Firm

New York, New York--(Newsfile Corp. - July 11, 2022) - Pomerantz LLP is investigating claims on behalf of investors of Applied Molecular Transport Inc. ("Applied Molecular" or the "Company") (NYSE: AMTI). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Applied Molecular and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Applied Molecular Transport Inc. - AMTI

Los Angeles, California--(Newsfile Corp. - July 11, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Applied Molecular Transport Inc. ("Applied Molecular" or "the Company") (NASDAQ: AMTI) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Applied Molecular issued a press release on July 6,...

INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in Applied Molecular Transport Inc. with Losses of $100,000 to Contact the Firm

LOS ANGELES--(BUSINESS WIRE)--The Schall Law Firm Encourages Investors in Applied Molecular Transport Inc. with Losses of $100,000 to Contact the Firm

INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Applied Molecular Transport Inc. with Losses of $100,000 to Contact the Firm

Applied Molecular Transport Inc (NASDAQ: AMTI) has announced topline Phase 2 results from the MARKET combination trial for AMT-101 in ulcerative colitis (UC).  In the MARKET trial, patients received either AMT-101 3mg combined with AbbVie Inc's (NYSE: ABBV) Humira.

Applied Molecular Shares Tumble After Disappointing Data From Mid-Stage Ulcerative Colitis Study

Live Conference Call and Webcast on Wednesday, July 6, 2022, at 8:30 a.m. ET (5:30 a.m. PT) Live Conference Call and Webcast on Wednesday, July 6, 2022, at 8:30 a.m. ET (5:30 a.m. PT)

Applied Molecular Transport to Report Top-line Phase 2 Results from MARKET Combination Trial of Oral AMT-101 in Patients with Moderate-to-Severe Ulcerative Colitis

Applied Molecular Transport Inc (NASDAQ: AMTI) will prioritize the advancement of AMT-101 into late-stage clinical development.  It is preparing for the end of Phase 2 meetings with the FDA to advance AMT-101 to Phase 3 in chronic pouchitis.

Applied Molecular Cuts Its Workforce By 40%, Pauses Early-Stage Research Programs

Company streamlines to prioritize resources on key proprietary clinical programs, including plans to advance AMT-101 into Phase 3 for chronic pouchitis

News for Applied Molecular Transport Stock (AMTI)